Sprint Bioscience Q2: Brief comment on the report - Redeye

Redeye provides a brief comment on Sprint Bioscience’s Q2 report. We will soon return with a more extensive take on the case in light of the VADA licensing agreement and where we will likely increase our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/937722/sprint-bioscience-q2-brief-comment-on-the-report?utm_source=finwire&utm_medium=RSS